Eight-cycle rituximab therapy resulted in complete remission in primary cutaneous marginal zone lymphoma.
Seker
Mesut
M
Ustaalioğlu
Bala Basak Oven
BB
Bilici
Ahmet
A
Yildirim
Mahmut Emre
ME
Kefeli
Umut
U
Barisik
Nagehan Ozdemir
NO
Tamer
Ismet
I
Gumus
Mahmut
M
D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000627:therapeutic use; D004334:Drug Administration Schedule; D019694:Hepatitis B, Chronic / Q000150:complications / Q000188:drug therapy; D006801:Humans; D016130:Immunophenotyping; D019259:Lamivudine / Q000627:therapeutic use; D018442:Lymphoma, B-Cell, Marginal Zone / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D012074:Remission Induction; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use; D000069283:Rituximab; D012878:Skin Neoplasms / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000998:Antiviral Agents; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine; D000069283:Rituximab